GSK forecasts slower sales growth in 2026

Group 1 - The core viewpoint of the article is that GSK forecasts a slowdown in sales growth by 2026 as the company, under new CEO Luke Miels, shifts its focus towards expanding its pipeline to address upcoming patent expirations [1] Group 2 - The new CEO's outlook marks a significant change in strategy for GSK, indicating a proactive approach to mitigate risks associated with patent expirations [1] - The emphasis on pipeline expansion suggests that GSK is prioritizing long-term growth and sustainability in its operations [1] - The forecasted slowdown in sales growth highlights potential challenges the company may face in maintaining revenue levels in the near future [1]